



Case Report Endocarditis with Streptococcus pseudoporcinus Associated with Mastocytosis and Spondylodiscitis—A Coincidental Association? A Case Report

Victoria Birlutiu^{1,*}, Rares-Mircea Birlutiu^{2,*}, Minodora Teodoru¹, Alina Camelia Catana³ and Cristian Ioan Stoica^{2,4}

- ¹ Faculty of Medicine, Lucian Blaga University of Sibiu, County Clinical Emergency Hospital Sibiu, Str. Lucian Blaga, Nr. 2A, 550169 Sibiu, Romania
- ² Clinical Hospital of Orthopedics, Traumatology, and Osteoarticular TB Bucharest, B-dul Ferdinand 35-37, Sector 2, 021382 Bucharest, Romania
- ³ County Clinical Emergency Hospital Sibiu, 550245 Sibiu, Romania
- ⁴ "Carol Davila" Faculty of Medicine, University of Medicine and Pharmacy, 050474 Bucharest, Romania
- Correspondence: victoriabirlutiu@yahoo.com (V.B.); raresmircea@gmail.com (R.-M.B.)

Abstract: *Streptococcus pseudoporcinus* is a nonmotile Gram-positive, catalase, and benzidine negative, arranged in short chains, isolated from the genitourinary tract group B Streptococcus. S. pseudoporcinus was also identified from blood, urine, skin, cervical area, wounds, rectum, and placenta samples. Two cases of infective endocarditis have been reported in the literature. Based on these data, the identification of a case of S. pseudoporcinus infective endocarditis associated with spondylodiscitis in a patient with undiagnosed systemic mastocytosis until the age of 63 years is unusual. Two sets of blood specimens were collected, and both sets were positive for S. pseudoporcinus. Transesophageal echocardiography revealed, multiple vegetations on the mitral valve. A lumbar spine MRI revealed L5-S1 spondylodiscitis that associates prevertebral and right paramedian epidural abscesses with compressive stenosis. The performed bone marrow biopsy, and cellularity examination revealed 5–10% mast cells in the areas of medullary tissue, an aspect that is suggestive of mastocytosis. Antibiotic therapy was initiated, under which the patient presented intermittent fever. A second transesophageal echocardiography revealed a mitral valve abscess. A mitral valve replacement with a mechanical heart valve device through a minimally invasive approach was performed, with a favorable evolution under treatment. S. pseudoporcinus can be responsible for infectious endocarditis in certain immunodepressed cases, but also in a profibrotic, proatherogenic field, as shown by the association with mastocytosis in the presented case.

Keywords: infective endocarditis; *Streptococcus pseudoporcinus*; systemic mastocytosis; spondylodiscitis; case report

1. Introduction

Streptococcus pseudoporcinus, has been reported in human pathology since 2006 when it was differentiated from *Streptococcus porcinus*, being isolated from the female genitourinary tract. Few cases of infections have been published up to this point, either localized infection, a case of post-traumatic wound infection [1], a case of lower limbs cellulitis [2], or in the last years, cases of systemic infections that suggest a significant virulence of this species, that should not be neglected. Two cases of infective endocarditis have been reported in the literature [3,4], a case of pneumonia complicated with empyema associated with *Prevotella oris* [3], and a case of bacteremia in an immunosuppressed patient with syphilis and HIV co-infections [5]. Vergadi et al. report a difficult-to-treat case of cellulitis associated with bacteremia in a pediatric patient with Klippel-Trenaunay syndrome [6], Liatsos et al. report spontaneous peritonitis in a patient with liver cirrhosis with unfavorable outcome [7], and



Citation: Birlutiu, V.; Birlutiu, R.-M.; Teodoru, M.; Catana, A.C.; Stoica, C.I. Endocarditis with *Streptococcus pseudoporcinus* Associated with Mastocytosis and Spondylodiscitis— A Coincidental Association? A Case Report. *Trop. Med. Infect. Dis.* **2023**, *8*, 247. https://doi.org/10.3390/ tropicalmed8050247

Academic Editors: Cristiane C. Lamas and Emanuele Durante-Mangoni

Received: 7 March 2023 Revised: 20 April 2023 Accepted: 22 April 2023 Published: 25 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). more recently, Dong et al. describe a case of orbital cellulitis resulting in corneal perforation, that required both antibiotic therapy and surgical intervention [8].

S. pseudoporcinus, a β -haemolytic Streptococcus of Lancefield groups E, P, V, U, NG1 (A1, C1), NG2, and NG3 [9], is a nonmotile Gram-positive, catalase, and benzidine negative, arranged in short chains, coccus, confused with group B Streptococcus, being isolated from the genitourinary tract like it (in Québec, Canada, 9 strains were differentiated between 1995–2005, from S. porcinus, by 16S rRNA gene sequencing). It has a spherical or ovoid shape and causes complete lysis on the Blood Agar culture medium, with an optimal growth between 10 °C and 45 °C (the temperature at which it no longer grows) being differentiated from S. porcinus by Bekal et al. in 2006 from a genetic point of view, using 16S rRNA gene sequencing [10]. Apart from its isolation from the genitourinary tract, S. pseudoporcinus was also identified from blood, urine, skin, cervical area, wounds, rectum, and placenta samples [9–12]. Genitourinary tract colonization appears to be more frequent in African American race, older age, and unmarried women, associated with poor education, local contraceptive measures (vaginal spermicides), and use of vaginal tampons. It is also reported the association with Trichomonas vaginalis infection or genital herpes [13]. Colonization with S. pseudoporcinus can be associated with smoking and a body mass index over 35 kg/m^2 , in pregnant women being responsible for premature or spontaneous premature birth [14]. Risk factors for a poor outcome are age, diabetes mellitus, high blood pressure, congestive heart failure, and immunosuppression [3–5,15, 16]. In terms of antibiotic susceptibility testing, S. pseudoporcinus is susceptible to betalactams, macrolides, glycopeptides, sulfamethoxazole/trimethoprim, and clindamycin, and is resistant to tetracycline [11]. Liatsos et al. isolates a multidrug resistance strain, a strain that was resistant to penicillin, third-generation cephalosporins, and carbapenems [7].

Based on these data, the identification of a case of *S. pseudoporcinus* infective endocarditis associated with spondylodiscitis in a patient with undiagnosed systemic mastocytosis until the age of 63 years is unusual.

2. Case Report

We describe the case of a 63-year-old Caucasian male patient, who lives in North America and Europe, and seeks medical advice for prolonged fever (38–39.8 °C), weight loss of 10 kg in 2 months, marked physical asthenia, and pain on the mobilization of the lumbar spine. In his past medical history, the patient was a heavy smoker, with a 45 pack-year cigarette smoking history; he was also hypertensive, with functional capacity IV, and objective assessment C heart failure using the New York Heart Association (NYHA) classification system, right bundle branch block, and first-degree atrioventricular heart block. At the time of admission, on physical examination, the following changes were noticed: thoracoabdominal erythematous papular infiltrative rash, holosystolic murmur, hepatosplenomegaly, and hypogastric abdominal tenderness. In the context of a prolonged febrile illness, that was not investigated until that moment for any possible etiologies, an investigation protocol was initiated by a multidisciplinary team (infectious disease specialist, hematologist, surgeon, cardiologist) that included laboratory and complementary imaging investigations.

The main laboratory examinations that were performed are presented in Table 1 and are highlighting an important biological inflammatory syndrome. Two sets of blood specimens drawn 12 h apart were collected from independent venipuncture sites during the day of admission, and both sets were positive for *S. pseudoporcinus*, a strain that was sensitive to ampicillin, cefotaxime, ceftriaxone, clindamycin, chloramphenicol, erythromycin, tetracycline, vancomycin, moxifloxacin, levofloxacin, linezolid, tigecycline and intermediately sensitive to penicillin. An automated blood culture system that includes BACT/ALERT®3D and BACT/ALERT®Culture Media (bioMérieux, Marcy-l'Étoile, France) was used. The isolated bacteria were identified using a VITEK 2 Compact analyzer (bioMérieux, Marcy-l'Étoile, France). Minimum inhibitory concentrations were assessed according to the EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints.

On admission C-Reactive Protein 114.81 mg/L 0-3 mg/L Fibringen 514 mg/dL 170-420 mg/dL WBCs 14.70 × 103/µL 42-7.55 × 103/µL Differential blood count: 11.77 × 103/µL 10.5 × 103/µL Lymphocytes 1.91 × 103/µL 10.5 × 103/µL Lymphocytes 1.91 × 103/µL 0.2 × 103/µL Basophils 0.02 × 103/µL 0.4 × 03/µL Basophils 0.02 × 103/µL 0.4 × 03/µL Heenolobil 10.3 g/dL 13-17 g/dL Heenolobil 10.3 g/dL 13-17 g/dL Heamolophils 0.05 × 103/µL 0.40 × 103/µL Heamolophils 0.05 × 103/µL 0.40 × 103/µL Heamolophils 0.05 × 103/µL 150-400 × 103/µL Red Blood Cells 3.3 × 10 ⁴ /µL 150-400 × 103/µL Heamolophils 10.3 g/dL 13-7 g/dL Heamolophils 10.3 g/dL 150-400 × 103/µL Strum protein electrophoresis: 11.0 0.86-1.1 Albumin 50.1% 53.3 < 65.5% Albuha- 2 jobulins <	Date	Parameter	Values	Reference Value
$\begin{tabular}{ c c c c c } \hline Fibrinogen & 514 mg/dl. & 170+420 mg/dl. \\ \hline WBCs & 14.70 \times 103/\muL & 42-75 \times 103/\muL \\ \hline Differential blood count: \\ & Neutrophils & 11.77 \times 103/\muL & 10 \times 103/\muL \\ & Igraphocytes & 0.95 \times 103/\muL & 021 \times 103/\muL \\ & Noncoytes & 0.95 \times 103/\muL & 021 \times 103/\muL \\ & 0.02 \times 103/\muL & 002 \times 103/\muL \\ & 0.02 \times 103/\muL & 002 \times 103/\muL \\ & 0.02 \times 103/\muL & 002 \times 103/\muL \\ \hline Red Blood Cells & 3.35 \times 10^6/\muL & 4.5.58 \times 10^6/\muL \\ \hline Hematoxrit & 30.6\% & 40-50\% \\ \hline Hrmatoxrit & 30.6\% & 40-50\% \\ \hline Thrombucytes & 1.70 \times 10^7/\muL & 150-400 \times 10^7/\muL \\ \hline Hematoxrit & 30.6\% & 40-50\% \\ \hline Coagulation tests & 120 \times 10^7/\muL & 150-400 \times 10^7/\muL \\ \hline Serum protein electrophoresis: \\ \hline Albumin & 50.1\% & 543-65.\% \\ \hline Alpha-2 globulins & 9.1\% & 53-1\% \\ \hline Red algodow & 9.1\% & 53-1\% \\ \hline Hernatoxrit & 50.1\% & 54-45.\% \\ \hline Hernatorin & 50.1\% & 54-45.\% \\ \hline Alpha-2 globulins & 9.1\% & 53-1\% \\ \hline Alpha-2 globulins & 9.1\% & 53-1\% \\ \hline Red algodow & 9.1\% & 53-1\% \\ \hline Red algodow & 9.1\% & 53-1\% \\ \hline Red algodow & 9.1\% & 53-1\% \\ \hline Hernatorin & 0.05 mg/dL & 70-0100 mg/dL \\ \hline Hernatorin & 0.95 mg/dL & 70-0100 mg/dL \\ \hline Hernatorine & 0.95 mg/dL & 0.72-1.25 mg/dL \\ \hline Color & -Vellow \\ \hline Clarity/Lurbidity-Clear \\ PuH-35 \\ \hline Supurnous epithelial cells-5-10 \\ \hline Supurnous epithelial cells-5-10 \\ \hline Supurnous epithelial cells-7-10 \\ \hline Urine Culture & E. coli >100,000 CFU/ML \\ \hline HIV-1/HIV-2 Antibody Test Negative \\ \hline Vurine Valued & Negative \\ \hline HIV-1/HIV-2 Antibody Test Negative \\ \hline HIV-1/HI$	On admission	C-Reactive Protein	114.81 mg/L	0–5 mg/L
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Fibrinogen	514 mg/dL	170–420 mg/dL
Differential blood count: Neutrophils 11.77 × 103/µL 10 × 103/µL Lymphocytes 1.91 × 103/µL 0.2-1 × 103/µL Basophils 0.02 × 103/µL 0.0-2 × 103/µL Basophils 0.02 × 103/µL 0-0.2 × 103/µL Red Blood Cells 3.35 × 10 ⁶ /µL 0-0.2 × 103/µL Hematocrit 30.6% 40-50% Thrombocytes 170 × 10 ³ /µL 150-400 × 10 ³ /µL Hematocrit 30.6% 40-50% Thrombocytes 170 × 10 ³ /µL 10-400 × 10 ³ /µL Coagulation tests 700 × 10 ³ /µL 10-400 × 10 ³ /µL Coagulation tests 100 × 103 /µL 9.9-12.3 s Activated partial thromboplasin time (PT): 30.9 251-37.7 s International normalized ratio (INR): 1.10 0.86-1.1 Serum protein electrophoresis: 411% 12-3.3% Alburnin 50.1% \$4,3-65.5% Alpha- 2 globulins 9.1% 83-15% Bota - globulins 13.7% 8.6-14.8% Camma-globulins 2.3% 7.1-19.5%		WBCs	$14.70 imes 103/\mu L$	$4.27.5\times103/\mu L$
Neutrophils 11/7 103/µL 10 10.5 × 103/µL laymphocytes 0.95 × 103/µL 0.2-1 × 103/µL 0.4-2 × 103/µL Basophils 0.05 × 103/µL 0.4-2 × 103/µL 0.4-0.2 × 103/µL Red Blood Cells 3.35 × 10 ⁶ /µL 4.5-58 × 10 ⁶ /µL Hemoglobin 10.3 g/dL 13-17 g/dL Hematocrit 3.06% 40-50% Thrombocytes 170 × 10 ³ /uL 150-400 × 10 ³ /uL Scauplation tests Activated partial thromboplastin time (aPT); 3.9 13.9 9.9-12.3 s Activated partial thromboplastin time (aPT); 30.9 251-37.7 s 110 International normalized ratio (INR): 1.10 0.86-1.1 Serum protein electrophoresis: 30.9 251-37.8 Albumin 50.1% 54.3-65.5% Alpha-2 globulins 9.1% 83-15% Beta-globulins 23% 7.1-19.3% IgG 1661 mg/dL 70-400 mg/dL IgG 1661 mg/dL 0.02-1.25 mg/dL Urea 34 mg/dL 18-55 mg/dL		Differential blood count:		10 100 / I
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Neutrophils	$11.77 \times 103/\mu L$ 1.01 × 102/L	$10 \times 103/\mu L$
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Monocytes	$1.91 \times 103/\mu L$ 0.95 × 103/µL	$1.5-4 \times 0.07 \mu\text{L}$
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Basophils	$0.93 \times 103 / \mu L$ $0.02 \times 103 / \mu L$	$0.2-1 \times 103/\mu L$ $0-0.2 \times 103/\mu L$
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Eosinophils	$0.02 \times 100/\mu L$ $0.05 \times 103/\mu L$	$0.2 \times 100 / \mu L$ $0-0.7 \times 103 / \mu L$
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Red Blood Cells	$3.35 imes 10^6/\mu L$	$4.5-5.8 \times 10^{6} / \mu L$
$\begin{tabular}{ c c c c c } \hline Hematocrit 30.6\% 40-50\% 150-400 \times 10^3/uL 150-400 \times 10^3/uL 150-400 \times 10^3/uL 13.9 9.9-12.3 s Prothrombin time (PT): 13.9 9.9-12.3 s Activated partial thromboplastin time (aPTT): 30.9 25.1-37.7 s International normalized ratio (INR): 1.10 0.86-1.1 Serum protein electrophoresis: Albumin 50.1% 54.3-66.5% Alpha-1 globulins 4.1% 1.2-3.3% 8.6-14.8% Gamma-globulins 13.7% 8.6-14.8% Gamma-globulins 23% 7.1-19.5% 7.1-19.5% 12.3 s Model 1.2 (Market Market Ma$		Haemoglobin	10.3 g/dL	13–17 g/dL
$\begin{tabular}{ c c c c } \hline Thrombocytes & 170 \times 10^3/uL & 150-400 \times 10^3/uL \\ \hline Prothrombin time (PT): & 13.9 & 9.9-12.3 s \\ \hline Activated partial thromboplastin time (aPT): & 30.9 & 25.1-37.7 s \\ \hline activated partial thromboplastin time (aPTT): & 30.9 & 25.1-37.7 s \\ \hline 1.10 & 0.86-1.1 & 0.86-1.8 & 0.88-1.1 & 0.86-1 & 0.86-1 & 0.86-1 & 0.86-1 & 0.86-1 & 0.86-1 & 0.86-1 &$		Hematocrit	30.6%	40-50%
Prothnombin time (PT): 13.99.9–12.3 sCoagulation testsActivated partial thromboplastin time (APTT): 30.925.1–37.7 sInternational normalized ratio (INR): 1.100.86–1.1Serum protein electrophoresis: Albumin50.1%54.3–65.5%Alpha-2 globulins4.1%1.2–3.3%Alpha-2 globulins9.1%8.3–15%Beta-globulins9.1%8.3–15%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins23.7%8.6–14.8%Gamma-globulins13.0%8.6–14.8%Gamma-globulins13.7%8.6–14.8%Gamma-globulins23.8%7.1–19.5%Sigamous-globulins9.615.5 <td></td> <td>Thrombocytes</td> <td>$170 \times 10^3/\mathrm{uL}$</td> <td>$150-400 \times 10^3/uL$</td>		Thrombocytes	$170 \times 10^3/\mathrm{uL}$	$150-400 \times 10^3/uL$
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Prothrombin time (PT):	
Coagulation tests Activated partial thromboplastin time (aPTT): 30.9 25.1-37.7 s International normalized ratio (INR): 0.86–1.1 Serum protein electrophoresis: Albumin 50.1% 54.3-65.5% Alpha-1 globulins 4.1% 1.2-3.3% Alpha-2 globulins 9.1% 8.3-15% Beta- globulins 9.1% 8.3-15% Gamma- globulins 1.3.7% 8.6-14.8% Gamma- globulins 2.3% 7.1-19.5% IgA 432 mg/dL 70-400 mg/dL IgA 133 mg/dL 40-230 mg/dL IgM 133 mg/dL 40-230 mg/dL IgM 133 mg/dL 40-230 mg/dL Urea 34 mg/dL 18-55 mg/dL Creatinine 0.95 mg/dL 0.72-1.25 mg/dL Blood glucose 128 mg/dL 80-115 mg/dL ColorYellow Clarity/ turbidityClear pH=-5.5 Specific gravity1.015 Glucose125 mg/d KetonesNone Urinalysis BilirubimNormal Blood-Negative Blood-Negative ViritesNegative Urinalysis BilirubimNormal Blood-Negative Urinalysis BilirubimStrine 0.23 MCS/hpf Squamous epithelial cells-hpf WBCs-2-3 WDCS/hpf WBCs-2-3 WDCS/hpf Squamous epithelial cells-hpf WBCs-2-3 WDCS/hpf </td <td></td> <td></td> <td>13.9</td> <td>9.9–12.3 s</td>			13.9	9.9–12.3 s
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Coagulation tests	Activated partial thromboplastin time	
30.9 25.1-57.7 s International normalized ratio (INR): 1.10 0.86-1.1 Serum protein electrophoresis: Albumin 50.1% 54.3-65.5% Alpha-1 globulins 4.1% 1.2-3.3% Alpha-2 globulins 9.1% 8.3-15% Beta-globulins 9.1% 8.3-15% Beta-globulins 23% 7.1-19.5% IgA 432 mg/dL 700-400 mg/dL IgG 1661 mg/dL 700-100 mg/dL IgG 1661 mg/dL 070-1600 mg/dL IgA 133 mg/dL 40-230 mg/dL Urea 34 mg/dL 18-55 mg/dL Color - Yellow Clarity/urbidity-Clear pH-5.5 Specific gravity-1.015 Glucose 128 mg/dL 80-115 mg/dL Older - Yellow Clarity/urbidity-Clear pH-5.5 Specific gravity-1.015 Glucose-125 mg/d Ketones-None NitritesNegative Virinelysis Urinalysis Bilorubin-Negative Urinalysis Bilorubin-Negative Virine-Culture E. coli>100.000 CFU/ML <td>0</td> <td>(aP11):</td> <td>0E 1 07 7 a</td>		0	(aP11):	0E 1 07 7 a
International formation frame (First). 1.10 0.86–1.1 Serum protein electrophoresis: 50.1% Albumin 50.1% Alpha-1 globulins 4.1% 1.2–3.3% Alpha-2 globulins 9.1% 8.3–15% Beta-globulins 9.1% 8.3–15% 8.4–14.8% Gamma-globulins 23% 7.1–19.5% 13,7% Bata-globulins 23% 1.10 700–400 mg/dL 1gG 1661 mg/dL 1gM 133 mg/dL 40–230 mg/dL 18–55 mg/dL 1gM 133 mg/dL 0.72–1.25 mg/dL 0.72–1.25 mg/dL 1gA 18–55 mg/dL 0.72–1.25 mg/dL 0.72–1.25 mg/dL 10 rea 34 mg/dL 80–115 mg/dL 110 rea 128 mg/dL 80–115 mg/dL 110 rea			30.9 International normalized ratio (INIR):	25.1–37.7 S
Serum protein electrophoresis: Albumin 50.1% $54.3-65.5\%$ Alpha-1 globulins 4.1% $1.2-3.3\%$ Alpha-2 globulins 9.1% $8.3-15\%$ Beta- globulins 9.1% $8.3-15\%$ Beta- globulins 9.1% $8.3-15\%$ Beta- globulins 9.1% $8.3-15\%$ $8.6-14.8\%$ Gamma- globulins 23% $7.1-19.5\%$ IgA432 mg/dL IgG70-400 mg/dL 100 mg/dLIgG1661 mg/dL 100-1600 mg/dLIgM133 mg/dL40-230 mg/dLESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLCreatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80-115 mg/dLColor — Yellow Clarity/turbidity—Clear pH=-5.5Specific gravity-1.015 Glucose-125 mg/d Ketones—None Nitrites—NegativeUrinalysisBilirubin—Normal Blood—NegativeBlood—Negative VBCSa-2-3 WBCS/hpf WBCSa-2-3 WBCS/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLUrine CultureHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative			1.10	0.86–1.1
Albumin50.1%54.3-65.5%Alpha-1 globulins4.1%1.2-3.3%Alpha-2 globulins9.1%8.3-15%Beta- globulins13.7%8.6-14.8%Gamma- globulins23%7.1-19.5%IgA432 mg/dL700-400 mg/dLIgG1661 mg/dL700-1600 mg/dLIgA133 mg/dL40-230 mg/dLESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLBlood glucose128 mg/dL80-115 mg/dLColorYellowClarity/turbidityClear pH-5.5Specific gravity1.015 Glucose-125 mg/dUrinalysisBilirubinNegative UrobilirubinNormal BloodNegativeNormal Blood-NegativeUrinalysisDilot-2.3 WBCS/hpf Squamous epithelial cells-/hpfWBCs-2-3 WBCS/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLUrine CultureHIV-1/HIV-2 Antibody TestNegativeNegative		Serum protein electrophoresis:		
$\begin{tabular}{ c c c c c } Alpha-1 globulins & 4.1% & 1.2-3.3% \\ Alpha-2 globulins & 9.1% & 8.3-15\% \\ Beta-globulins & 13.7\% & 8.6-14.8\% \\ Camma-globulins & 23\% & 7.1-19.5\% \\ \hline IgA & 432 mg/dL & 70-400 mg/dL \\ IgG & 1.661 mg/dL & 700-1600 mg/dL \\ IgM & 133 mg/dL & 40-230 mg/dL \\ \hline ESR* & 74 mm/h & 0-15 mm/h \\ \hline Urea & 34 mg/dL & 18-55 mg/dL \\ \hline Creatinine & 0.95 mg/dL & 0.72-1.25 mg/dL \\ \hline Blood glucose & 128 mg/dL & 80-115 mg/dL \\ \hline Clarity/turbidity-Clear \\ pfI-5.5 \\ Specific gravity-1.015 \\ Glucose-125 mg/d \\ \hline Urinalysis & Bilirubin-Negative \\ \hline Urinalysis & Bilirubin-Negative \\ \hline Urinalysis & Bilirubin-Stare \\ \hline HIV-1/HIV-2 Antibody Test & Negative \\ \hline Rapid plasma reagin & Negative \\ \hline \end{tabular}$		Albumin	50.1%	54.3-65.5%
Alpha-2 globulins9.1% $8.3-15\%$ Beta-globulins 13.7% $8.6-14.8\%$ Gamma-globulinsIgA432 mg/dL $70-400$ mg/dL IgG 1661 mg/dL $700-1600$ mg/dLIgA133 mg/dL $40-230$ mg/dLIgM133 mg/dL $40-230$ mg/dLESR* 74 mm/h $0-15$ mm/hUrea 34 mg/dL $18-55$ mg/dLCreatinine 0.95 mg/dL $0.72-1.25$ mg/dLBlood glucose 128 mg/dL $80-115$ mg/dLColor — VellowClarity/turbidity—Clear pH= -5.5 Specific gravity=1.015 Glucose=-125 mg/d Ketones=-None Nitrites—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf Squamous epithelial cells/hpfUrine Culture $E. coli > 100,000$ CFU/MLHIV-1/HIV-2 Antibody TestNegativeKapid plasma reaginNegative		Alpha-1 globulins	4.1%	1.2–3.3%
Beta-globulins 13.7% $8.6-14.8\%$ Gamma-globulinsIgA 23% $7.1-19.5\%$ IgA $432 mg/dL$ $70-400 mg/dL$ IgG1661 mg/dL $700-1600 mg/dL$ IgM $133 mg/dL$ $40-230 mg/dL$ ESR* $74 mm/h$ $0-15 mm/h$ Urea $34 mg/dL$ $18-55 mg/dL$ Blood glucose $128 mg/dL$ $0.72-1.25 mg/dL$ Blood glucose $128 mg/dL$ $80-115 mg/dL$ Blood glucose $128 mg/dL$ $80-115 mg/dL$ UrinalysisBilirubin-Negative $WE0s=-25$ UrinalysisBilirubin-NegativeUrinalysisBilirubin-NegativeUrinalysisBilirubin-NegativeUrinalysisBilirubin-Sc/hpfSquamous epithelial cells/hpfUrine Culture $E. coli > 100,000$ CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative		Alpha-2 globulins	9.1%	8.3–15%
Camma-globulins23%7.1-19.5%IgA432 mg/dL70-400 mg/dLIgG1661 mg/dL700-1600 mg/dLIgM133 mg/dL40-230 mg/dLESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLCreatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80-115 mg/dLColor —YellowClarity/turbidity—Clear pH=5.5Specific gravity=1.015 Glucose=125 mg/dVirinalysisBilirubin—Normal Biloud—Negative Urobilirubin—Normal Blood—Negative Protein=100 mg/d RBCs=-1-2 RBCs/hpfVBCs-2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegativeNegative		Beta- globulins	13.7%	8.6-14.8%
$\begin{tabular}{ lgA } & 432 mg/dL & 70-400 mg/dL \\ lgG & 1661 mg/dL & 700-1600 mg/dL \\ lgM & 133 mg/dL & 40-230 mg/dL \\ \hline ESR* & 74 mm/h & 0-15 mm/h \\ \hline Urea & 34 mg/dL & 18-55 mg/dL \\ \hline Creatinine & 0.95 mg/dL & 0.72-1.25 mg/dL \\ \hline Creatinine & 0.95 mg/dL & 80-115 mg/dL \\ \hline Blood glucose & 128 mg/dL & 80-115 mg/dL \\ \hline ColorYellow \\ Clarity/turbidity-Clear \\ pH-5.5 \\ Specific gravity1.015 \\ Glucose125 mg/d \\ KetonesNone \\ NitritesNegative \\ Urinalysis & BilirubinNormal \\ BloodNegative \\ Urobilirubin-Normal \\ BloodNegative \\ Protein-100 mg/d \\ RBCs-1-2 RBCs/hpf \\ WBCs-2-3 WBCs/hpf \\ Squamous epithelial cells-5-10 \\ squamous epithelial cells-5-10 \\ squamous epithelial cells/hpf \\ \hline Urine Culture & E. coli >100,000 CFU/ML \\ \hline HIV-1/HIV-2 Antibody Test \\ Rapid plasma reagin \\ Negative \\ \hline \end{tabular}$		Gamma- globulins	23%	7.1–19.5%
IgG1661 mg/dL700-1600 mg/dLIgM133 mg/dL40-230 mg/dLESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLCreatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80-115 mg/dLColorYellow Clarity/turbidtyClear pH-5.5Specific gravity1.015 Glucose-125 mg/dUrinalysisBilirubin-Negative Urobilirubin-Negative Urobilirubin-Normal Blood-Negative Protein-100 mg/d RBCs2-3 WBCs/hpf Squamous epithelial cells-5-10 squamous epithelial cells/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative		IgA	432 mg/dL	70–400 mg/dL
IgM133 mg/dL40–230 mg/dLESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLCreatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80–115 mg/dLColor —Yellow Clarity/turbidity—Clear pH—5.580–115 mg/dLColor —Yellow Clarity/turbidity—Clear pg/dL60–115 mg/dLUrinalysisSilirubin—Negative Urobilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative		IgG	1661 mg/dL	700–1600 mg/dL
ESR*74 mm/h0-15 mm/hUrea34 mg/dL18-55 mg/dLCreatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80-115 mg/dLColor —Yellow Clarity/turbidity—Clear pH—5.5Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urobilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative		IgM	133 mg/dL	40–230 mg/dL
Urea34 mg/dL18–55 mg/dLCreatinine0.95 mg/dL0.72–1.25 mg/dLBlood glucose128 mg/dL80–115 mg/dLColor —Yellow Clarity/turbidity—Clear pH—5.5Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—NegativeUrinalysisBilirubin—Negative Urobilrubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative		ESR*	74 mm/h	0–15 mm/h
Creatinine0.95 mg/dL0.72-1.25 mg/dLBlood glucose128 mg/dL80-115 mg/dLColor —YellowClarity/turbidity—Clear pH—5.5Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urobilirubin—Negative Urobilirubin—Negative WBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf100 mg/d RBCs/hpfUrine Culture <i>E. coli</i> >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeHIV-1/HIV-2 Antibody TestNegativeNegative		Urea	34 mg/dL	18–55 mg/dL
Blood glucose 128 mg/dL 80–115 mg/dL Color —Yellow Clarity/turbidity—Clear pH—5.5 Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpf Urine Culture <i>E. coli</i> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative		Creatinine	0.95 mg/dL	0.72–1.25 mg/dL
Color —Yellow Clarity/turbidity—Clear pH—5.5 Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpf Iurine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative		Blood glucose	128 mg/dL	80–115 mg/dL
Clarity/turbidity—Clear pH—5.5 Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Urine Culture <i>E. coli</i> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative		Urinalycic	Color —Yellow	
Specific gravity—1.015 Glucose—125 mg/d Ketones—None Nitrites—Negative Urinalysis Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Urine Culture <u>E. coli</u> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Rapid plasma reagin Negative			Clarity/turbidity—Clear	
Glucose—125 mg/d Glucose—125 mg/d Ketones—None Nitrites—Negative Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Urine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			p_{Π} = 0.5	
Ketones-None Nitrites-Negative Nitrites-Negative Nitrites-Negative Urinalysis Bilirubin-Normal Blood-Negative Protein-100 mg/d RBCs-1-2 RBCs/hpf WBCs-2-3 WBCs/hpf Squamous epithelial cells-5-10 squamous epithelial cells/hpf Image: Contract of the second seco			Chucoso 125 mg/d	
Nitrites—Negative Vrinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Urine Culture <i>E. coli</i> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			Ketones—None	
Urinalysis Bilirubin—Negative Urobilirubin—Normal Blood—Negative Protein—100 mg/d RBCs—1-2 RBCs/hpf WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Image: State of the state			Nitrites-Negative	
Offinition Negative Urobilirubin Normal Blood Negative Protein 100 mg/d RBCs 1–2 RBCs/hpf WBCs 2–3 WBCs/hpf Squamous epithelial cells 5–10 squamous epithelial cells/hpf 100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			Bilirubin—Negative	
Blood—Negative Protein—100 mg/d RBCs—1–2 RBCs/hpf WBCs—2–3 WBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpf Urine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative		01111119313	Urobilirubin—Normal	
Protein—100 mg/d RBCs—1–2 RBCs/hpf WBCs—2–3 WBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpf Urine Culture <i>E. coli</i> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			Blood—Negative	
RBCs—1–2 RBCs/hpf WBCs—2–3 WBCs/hpf Squamous epithelial cells—5–10 squamous epithelial cells/hpf Urine Culture <i>E. coli</i> >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			Protein—100 mg/d	
WBCs—2-3 WBCs/hpf Squamous epithelial cells—5-10 squamous epithelial cells/hpf Urine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			RBCs—1–2 RBCs/hpf	
Squamous epithelial cells—5–10 squamous epithelial cells/hpf Urine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			WBCs—2–3 WBCs/hpf	
squamous epithelial cells/hpf Urine Culture E. coli >100,000 CFU/ML HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative			Squamous epithelial cells—5–10	
Urine CultureE. coli >100,000 CFU/MLHIV-1/HIV-2 Antibody TestNegativeRapid plasma reaginNegative			squamous epithelial cells/hpf	
HIV-1/HIV-2 Antibody Test Negative Rapid plasma reagin Negative		Urine Culture	<i>E. coli</i> >100,000 CFU/ML	
Rapid plasma reagin Negative		HIV-1/HIV-2 Antibody Test	Negative	
		Rapid plasma reagin	Negative	

 Table 1. Laboratory examinations during hospitalization.

Date	Parameter	Values	Reference Value
12 days after admission	C-Reactive Protein	26.77 mg/L	
	Fibrinogen	364 mg/dL	
	WBCs	$18.69 \times 103/\mu L$	
	Haemoglobin	11.4 g/dL	
	Hematocrit	34.4 %	
	Thrombocytes	$155 imes103/\mu L$	
19 days after admission	C-Reactive Protein	26.45 mg/L	
	Fibrinogen	443.9 mg/dL	
	WBCs	$14.93 imes 103/\mu L$	
	Haemoglobin	11.8 g/dL	
	Hematocrit	35.8 %	
	Thrombocytes	$187 imes 103/\mu L$	
-	ESR *	16 mm/h	

Table 1. Cont.

* ESR (erythrocyte sedimentation rate).

Transthoracic echocardiography was also performed and revealed the following data: intact interatrial septum, free left atrial appendage, mobile mitral valve—posterior leaflet shows prolapse and two mobile vegetations attached to the middle scallop (P2) segment. Regarding the first vegetation: oval-shaped vegetative formation of 15/8 mm with prolapse through the valve into the left ventricle. Regarding the second vegetation: filamentous mobile vegetative formation of 12 mm. Echogenic anterior mitral valve leaf with a 9.5 mm vegetation that was attached to the anteromiddle (A2) segment, without chordae breakage, severe mitral regurgitation jets. First vegetation prolapse and posterior mitral valve prolapse with 2 jets with vena contracta width of 5- and 3.5-mm. Conclusions: Multiple vegetations on the anterior and posterior leaflets of the mitral valve. Massive mitral insufficiency. Also, a transesophageal echocardiography was performed, and detailed information is reported in Figure 1.

ECG revealed frequent premature ventricular contractions (PVCs), (Figure 1A, black arrowheads) including couplets (Figure 1A, connected arrowheads), trigeminate PVCs (Figure 1B, black arrowheads), and an isolated premature supraventricular complex—PSVC (Figure 1B white line showing premature atrial depolarization, white arrowhead showing subsequent ventricular depolarization). Transthoracic echography revealed prolapse of the posterior mitral valve (VM), which presented two mobile vegetations attached to P2 and one mobile vegetation on the anterior mitral valve associated with severe mitral regurgitation. This was followed up by transesophageal echocardiography, which better defined the two vegetations on the posterior mitral valve: one measuring approximately 12 mm in diameter (Figure 1C—ME 2 chambers) and the other measuring approximately 15/8 mm (Figure 1D—ME 2 chambers) and prolapsing through the mitral orifice; as well as the vegetation on the anterior mitral valve (9.5 mm diameter) (Figure 1E—ME LAX). In addition, the posterior mitral valve showed prolapse. Mitral regurgitation was quantified as severe, with two jets (Figure 1F-ME 2 chambers, color doppler; green arrowheads show the two jets, VC1 = 5 mm; VC2 = 3.5 mm). Transthoracic echocardiographic reevaluation one week later revealed a new vegetation at the base of the posterior mitral valve with dimensions of approximately 10/11 mm (Figure 1G—A4C) accompanied by a new mitral regurgitation jet at the same location (Figure 1H—A4C, color doppler; green arrowhead showing previous central jet, green arrow showing newly discovered jet, vena contracta = 3 mm), raising the suspicion of a valvular abscess with consequent perforation. Surgery for mitral mechanical valve implantation occurred without complications (Figure 1I showing



the postoperative transthoracic echocardiographic aspect of the mitral valve; A4C with continuous doppler flow measuring mitral valve velocity time integral (MV-VTI)).

Figure 1. ECG, Transthoracic and transesophageal echocardiography examinations preoperative and postoperative.

A lumbar spine magnetic resonance imaging (MRI) was also performed, and the following results were reported: narrowing of the L5-S1 intervertebral space with discretely irregular edges of the adjacent vertebral end plates, with moderate disc edema and "mirror" edema at the level of the vertebral end plates. Linear progressive contrast uptake at the level of the vertebral end plateaus adjacent to the L5-S1 intervertebral disc, with fluid collections with contrast outline uptake at the anterior prevertebral L5-S1 soft tissues. At a posterior paramedian right intervertebral disc and epidural level compressive stenosis. Conclusions:

patchy gadolinium uptake edema, L5-S1 spondylodiscitis that associates prevertebral and right paramedian epidural abscesses with compressive stenosis. A T2-weighted image from the MRI study is reported in Figure 2.



Figure 2. MRI scans of the lumbar spine. A T2-weighted image MRI studies.

Laboratory examinations also reveal hypergammaglobulinemia (increased IgG and IgA levels), and nonmonoclonal increased kappa and lambda light chains. Serum tryptase levels of 69μ g/L (reference values 0–20 μ g/L), and peripheral blood c-KIT were slightly positive. A bone marrow biopsy was performed, and cellularity examination revealed 5–10% mast cells in the areas of medullary tissue, an aspect that is suggestive of mastocytosis. It was recommended to assess the result together with the anatomopathological examination and immunophenotyping for the most accurate assessment of mastocytosis. Immunophenotyping was performed using the CD45, CD117, CD34, CD203, HLADR, CD123 panel that identified the following cell populations: Mast cells CD117+/CD203+, CD34-/HLADR-, CD123-, CD25+, CD2+ 0.15% mast cells. The conclusion of the immunophenotyping examination was that the bone marrow is infiltrated with mature, pathological CD25+/CD2+ mast cells, in a percentage of 0.15%. Bone marrow biopsy aspects are reported in Figure 3.

Bone marrow biopsy anatomopathological examination reveals a focal reactive bone marrow type I aspect with mast cell infiltrates. Skin biopsy does not reveal mast cell proliferation on the examined specimens. Detection of the c-KIT mutation was performed by molecular biology and was weakly positive for D816V.

From sputum, sperm, and urine culture *Escherichia Coli* was isolated, and also *Enter*obacter aerogenes was isolated from sputum cultures. Both isolated strains were susceptible to 3rd- and 4th-generation cephalosporins, carbapenems, aminoglycosides, and piperacillintazobactam. Antibiotic therapy was initiated with ceftriaxone 2 g/day and vancomycin 2×1 g/day, under which the patient presented intermittent fever. 10 days after the first transethoracic echocardiography, a second one is performed and revealed a hyperechoic, oval-shaped formation of 11/10 mm at the base of the posterior leaflet of the mitral valve, an aspect that might suggest an abscess, with a possible valve perforation at this level, mitral regurgitation through 3 jets: central, eccentric and a jet through the back leaflet (perforation?) with vena contracta width of 3 mm.

The decision to undergo surgical intervention was taken, and the patient was referred to the cardiovascular surgical department, where a mitral valve replacement with a St. Jude Medical no. 31 mechanical heart valve fixed with COR-KNOT device through a minimally invasive approach was performed. From the harvested hemocultures prior to the surgery and the bacteriological examination of the vegetation no pathogens were isolated. Histopathological examination of the resected tissue revealed: a white membraniform tissue fragment, with an irregular contour, elastic consistency, and $3 \times 2 \times 1$ cm in size. On microscopic examination, the examined tissue is represented by a fibro-conjunctival

structure with collagen fibers, with hyalinization and focal calcifications, that associates acute and chronic non-specific adjacent inflammatory process, with the giant-cellular granulomatous process, rich vascularization and fibrosis (reparative/scarring context). The treatment with ceftriaxone was continued for up to 4 weeks and later, at discharge, with levofloxacin 750 mg/day, another 2 months for the L5-S1 spondylodiscitis, with a favorable evolution under treatment. The patient remained under cardiological follow-up and is under long-term therapy with anticoagulant, antiplatelet, hypotensive, and statin therapy. The favorable evolution of the patient was the result of an interdisciplinary collaboration between multiple specialists, who helped caring this case.



Figure 3. Bone marrow biopsy aspects and cellularity examination. (**A**,**B**)—May Grunwald-Giemsa, active macrophages in the medullary tissue areas, mast cells between 5–10%. (**C**)—May Grunwald-Giemsa staining.

3. Discussion

Mastocytosis is a condition associated with the proliferation and excessive accumulation of cutaneous (cutaneous mastocytosis) or systemic mastocytes, which is responsible for the activation and release of vasoactive cellular mediators (histamine, cytokine, tumor necrosis factor, growth factors, protease, and phospholipases), triggering a polymorphism of symptoms from anaphylaxis, to pruritus, or gastrointestinal manifestations (nausea, vomiting, diarrhea, abdominal pain, peptic ulcer, gastrointestinal bleeding, etc.), musculoskeletal disorders (bone and muscle pain similar to fibromyalgia), osteopenia/osteoporosis, psychiatric manifestations (the so-called "mixed organic brain syndrome"), lymphadenopathy, hepatosplenomegaly, hematological changes (anemia, and less often eosinophilia). The real incidence of mastocytosis is not known, but it affects both genders equally, the cutaneous form is mostly diagnosed in childhood, while the systemic form is present in 95% of cases in adults [17]. The most common genetic mutation responsible for systemic mastocytosis is KIT D816V, less often other mutations such as FIP1L1-PDGFR, TET2, IgE, JAK2 V617F, and RAS are also responsible. Cardiac involvement may be suggested by recurrent syncope, Kounis syndrome (acute coronary syndrome induced by mast cell degranulation by coronary spasm, coronary artery occlusion, or rupture of preexisting atherosclerotic plaque secondary to mast cell activation) [18,19], increased risk of myocardial infarction [20], or sudden death [21]. The proatherogenic role of mastocytosis is recognized, and also an inducer of fibrogenesis [22,23].

The updated diagnostic criteria of mastocytosis are reported by Valent P et al. Major criterion: Multifocal dense infiltrates of mast cells (\geq 15 mast cells in aggregates) in bone marrow biopsies and/or in sections of other extracutaneous organ(s). Minor criteria: a. \geq 25% of all mast cells are atypical cells (type I or type II) on bone marrow smears or are spindle-shaped in mast cell infiltrates detected in sections of bone marrow or other extracutaneous organ; b. KIT-activating KIT point mutation(s) at codon 816 or in other critical regions of KITb in bone marrow or another extracutaneous organ; c. Mast cells in bone marrow, blood, or another extracutaneous organ express one or more of: CD2 and/or CD25 and/or CD30c; d. Baseline serum tryptase concentration >20 ng/mL (in the case of an unrelated myeloid neoplasm, an elevated tryptase does not count as an systemic mastocytosis criterion. In the case of a known hereditary alpha-tryptasemia, the tryptase level should be adjusted. If at least 1 major and 1 minor or 3 minor criteria are fulfilled \rightarrow the diagnosis is systemic mastocytosis [24]

The diagnosis of systemic mastocytosis in our case report was established based on the presence of 1 major (the presence of mast cells in the bone marrow biopsy tissue) and 3 minor criteria (KIT-activating KIT point mutation at codon 816, CD25+ mast cells in bone marrow, and baseline serum tryptase concentration >20 ng/mL). Concomitant vertebral and cardiac impairment may be the consequence of the lesions associated with mastocytosis, which would explain the rapid evolution towards perforation of the mitral valve through the profibrotic pathways. Although it is the only case of systemic mastocytosis reported in the literature to date, which associates infective endocarditis caused by a pathogen rarely encountered in human pathology, we consider that it is important to include in the possible cardiovascular diseases associated with mastocytosis also infective endocarditis. The association of infective endocarditis with S. pseudoporcinus with pneumonia or pulmonary empyema [3], on aortic valve [4], associated with chronic obstructive pulmonary disease (COPD), mitral valve prolapses, and history of pulmonary embolism [25], in pregnant women [26] was described, but never in the infective endocarditis-spondylodiscitis-mastocytosis triad. In terms of the limitations of our case report, they are related to the lack of etiological diagnosis of spondylodiscitis, the case being treated conservatively and not surgically.

4. Conclusions

S. pseudoporcinus can be responsible for infectious endocarditis in certain immunodepressed cases, but also in a profibrotic, proatherogenic field, as shown by the association with mastocytosis in the presented case.

Author Contributions: Conceptualization, V.B.; methodology, R.-M.B. and V.B.; software, R.-M.B.; validation, R.-M.B., V.B., M.T., A.C.C. and C.I.S.; formal analysis, R.-M.B., V.B., M.T., A.C.C. and C.I.S.; investigation, V.B., M.T., A.C.C.; resources, R.-M.B., V.B. and C.I.S.; data curation, R.-M.B.; writing—original draft preparation, V.B.; writing—review and editing, R.-M.B., M.T., A.C.C.; visualization, R.-M.B., M.T., A.C.C. and V.B.; supervision, V.B., C.I.S. All authors have read and agreed to the published version of the manuscript.

Funding: Project financed by Lucian Blaga University of Sibiu through the research grant LBUS-IRG-2022-08.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. The study was accepted by the Ethics Committee of the Emergency Clinical County Hospital Sibiu, Romania and they encouraged publishing the article (ID:4578/27.02.2023). All methods were carried out following relevant guidelines and regulations.

Informed Consent Statement: Informed consent was obtained from the patient for publication of their case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Data Availability Statement: All data generated or analyzed during this study are included in this published article.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Mahlen, S.D.; Clarridge, J.E. III Thumb infection caused by *Streptococcus pseudoporcinus*. J. Clin. Microbiol. 2009, 47, 3041–3042. [CrossRef]
- Sawamura, S.; Niimori, D.; Ihn, H. A case of leg cellulitis caused by multidrug-resistant *Streptococcus pseudoporcinus*. *Intractable Rare Dis. Res.* 2018, 7, 280–282. [CrossRef] [PubMed]
- 3. Khan, S.; Wong, T.T.; Prasad, N.; Lee, B.; Urban, C.; Segal-Maurer, S.; Turett, G. *Streptococcus pseudoporcinus*: Case Reports and Review of the Literature. *Case Rep. Infect. Dis.* **2020**, 2020, 4135246. [CrossRef] [PubMed]
- 4. Hai, P.D.; Dung, N.M.; Son, P.N.; Phuong, L.L.; Thuyet, B.T.; Hoa, L.V. First report of infective endocarditis caused by *Streptococcus pseudoporcinus* in Vietnam. *New Microbes New Infect.* **2020**, *34*, 100643. [CrossRef] [PubMed]
- 5. Gupta, K.; Mohanty, M.; Rath, S. Bacteremia because of *Streptococcus pseudoporcinus* in a Syphilis-HIV co-infected patient: A case report. *J. Fam. Med. Prim. Care* 2020, *9*, 2119–2120. [CrossRef]
- 6. Vergadi, E.; Goniotakis, I.; Maraki, S.; Galanakis, E. Extensive Cellulitis and Bacteremia Due to *Streptococcus Pseudoporcinus* in a Child With Klippel-Trenaunay Syndrome. *Pediatr. Infect. Dis. J.* **2021**, *40*, e316–e318. [CrossRef]
- 7. Liatsos, G.D.; Tsiriga, A.; Dourakis, S.P. Fatal *Streptococcus pseudoporcinus* disseminated infection in decompensated liver cirrhosis: A case report. *J. Med. Case Rep.* **2021**, *15*, 240. [CrossRef]
- 8. Dong, Y.; Tian, M. Case Report: Corneal perforation secondary to orbital cellulitis caused by *Streptococcus pseudoporcinus* infection. *Eur. J. Ophthalmol.* **2022**, *4*, 11206721221085210. [CrossRef]
- Facklam, R.; Elliott, J.; Pigott, N.; Franklin, A.R. Identification of *Streptococcus porcinus* from human sources. *J. Clin. Microbiol.* 1995, 33, 385–388. [CrossRef]
- 10. Bekal, S.; Gaudreau, C.; Laurence, R.A.; Simoneau, E.; Raynal, L. *Streptococcus pseudoporcinus* sp. nov., a novel species isolated from the genitourinary tract of women. *J. Clin. Microbiol.* **2006**, *44*, 2584–2586. [CrossRef]
- Gaudreau, C.; Simoneau, E.; Labrecque, O.; Laurence, R.A.; Laferrière, C.; Miller, M.; Raynal, L.; Rallu, F. Epidemiological, biochemical and antimicrobial susceptibility characteristics of *Streptococcus pseudoporcinus* isolated in Quebec, Canada, from 1997 to 2006. J. Med. Microbiol. 2007, 56 Pt 12, 1620–1624. [CrossRef]
- 12. Martin, C.; Fermeaux, V.; Eyraud, J.L.; Aubard, Y. *Streptococcus porcinus* as a cause of spontaneous preterm human stillbirth. *J. Clin. Microbiol.* **2004**, *42*, 4396–4398. [CrossRef] [PubMed]
- Stoner, K.A.; Rabe, L.K.; Austin, M.N.; Meyn, L.A.; Hillier, S.L. Incidence and epidemiology of *Streptococcus pseudoporcinus* in the genital tract. J. Clin. Microbiol. 2011, 49, 883–886. [CrossRef] [PubMed]
- 14. Grundy, M.; Suwantarat, N.; Rubin, M.; Harris, R.; Hanlon, A.; Tekle, T.; Ellis, B.; Carroll, K.; Witter, F. Differentiating *Streptococcus* pseudoporcinus from GBS: Could this have implications in pregnancy? *Am. J. Obstet. Gynecol.* **2019**, 220, 490.e1–490.e7. [CrossRef]
- 15. Akagi, M.; Iwanaga, N.; Torisu, Y.; Fujita, H.; Kawahara, C.; Horai, Y.; Izumi, Y.; Kawakami, A. IgA Vasculitis Triggered by Infective Endocarditis of Pulmonary Artery with Congenitally Corrected Transposition of the Great Arteries. *Int. Heart J.* **2020**, *61*, 404–408. [CrossRef] [PubMed]
- 16. Pierce, S.L.; Shibib, D.R.; Robison, D.; Edwards, R.K. A case of maternal sepsis and fetal demise associated with *Streptococcus* pseudoporcinus. *Case Rep. Obstet. Gynecol.* **2019**, 2019, 4309191. [CrossRef] [PubMed]
- Wolff, K.; Komar, M.; Petzelbauer, P. Clinical and histopathological aspects of cutaneous mastocytosis. *Leuk. Res.* 2001, 25, 519–528. [CrossRef]
- 18. Kounis, N.G.; Zavras, G.M. Histamine-induced coronary artery spasm: The concept of allergic angina. *Br. J. Clin. Pract.* **1991**, 45, 121–128.
- 19. Abdelghany, M.; Subedi, R.; Shah, S.; Kozman, H. Kounis syndrome: A review article on epidemiology, diagnostic findings, management and complications of allergic acute coronary syndrome. *Int. J. Cardiol.* **2017**, 232, 1–4. [CrossRef]
- Broesby-Olsen, S.; Farkas, D.K.; Vestergaard, H.; Hermann, A.P.; Møller, M.B.; Mortz, C.G.; Kristensen, T.K.; Bindslev-Jensen, C.; Sørensen, H.T.; Frederiksen, H. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. *Am. J. Hematol.* 2016, *91*, 1069–1075. [CrossRef]
- 21. Paratz, E.D.; Khav, N.; Burns, A.T. Systemic Mastocytosis, Kounis Syndrome and Coronary Intervention: Case Report and Systematic Review. *Heart Lung Circ.* 2017, 26, 772–778. [CrossRef] [PubMed]
- 22. Kokkonen, J.O.; Kovanen, P.T. Stimulation of mast cells leads to cholesterol accumulation in macrophages in vitro by a mast cell granule-mediated uptake of low density lipoprotein. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 2287–2291. [CrossRef] [PubMed]
- 23. Kovanen, P.T. Mast Cell Granule-Mediated Uptake of Low Density Lipoproteins by Macrophages: A Novel Carrier Mechanism Leading to the Formation of Foam Cells. *Ann. Med.* **1991**, *23*, 551–559. [CrossRef] [PubMed]

- Valent, P.; Akin, C.; Hartmann, K.; Alvarez-Twose, I.; Brockow, K.; Hermine, O.; Niedoszytko, M.; Schwaab, J.; Lyons, J.J.; Carter, M.C.; et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. *Hemasphere* 2021, 5, e646. [CrossRef] [PubMed]
- 25. Peir-Yu, F.; Gandhi, S.A. *Streptococcus pseudoporcinus* subacute mitral valve endocarditis: A case report. *Int. J. Case Rep. Images* **2017**, *8*, 105–107.
- Cancan Gursul, N.; Ozdemir, E. Streptococcus porcinus Endocarditis: The First Reported Case In Humans. Eskisehir Med. J. 2022, 3, 1–4. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.